Get the Stockscreener App
767.76
1.35%
10.22
After Hours:
767.76
Overview
News
Price History
Option Chain
Financials
Why LLY Down?
Discussions
Forecast
Stock Split
Dividend History
Lilly Eli Co stock is traded at $767.76, with a volume of 8.93M.
It is up +1.35% in the last 24 hours and up +1.90% over the past month.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
See More
Previous Close:
$757.54
Open:
$811.35
24h Volume:
8.93M
Relative Volume:
2.49
Market Cap:
$690.46B
Revenue:
$40.86B
Net Income/Loss:
$8.37B
P/E Ratio:
141.67
EPS:
5.4193
Net Cash Flow:
$-2.28B
1W Performance:
-2.71%
1M Performance:
+1.90%
6M Performance:
-13.34%
1Y Performance:
+34.65%
1-Day Range:
$766.61
$811.35
1-Week Range:
$752.39
$811.35
52-Week Range:
$567.02
$972.53
Lilly Eli Co Stock (LLY) Company Profile
Name
Lilly Eli Co
Sector
Industry
Phone
(317) 276-2000
Address
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Compare LLY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
767.76 | 690.46B | 40.86B | 8.37B | -2.28B | 9.25 |
|
NVO
Novo Nordisk Adr
|
85.00 | 377.54B | 39.36B | 13.79B | 9.83B | 3.086 |
|
JNJ
Johnson Johnson
|
144.47 | 347.83B | 87.70B | 14.68B | 19.03B | 6.05 |
|
ABBV
Abbvie Inc
|
175.58 | 310.27B | 55.53B | 5.12B | 15.62B | 2.88 |
|
MRK
Merck Co Inc
|
98.05 | 248.03B | 63.17B | 12.15B | 14.84B | 4.77 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Sep-13-24 | Resumed | Citigroup | Buy |
| Aug-12-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-21-24 | Downgrade | DZ Bank | Buy → Hold |
| Feb-16-24 | Reiterated | Morgan Stanley | Overweight |
| Dec-21-23 | Downgrade | Daiwa Securities | Buy → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-20-23 | Resumed | UBS | Buy |
| Aug-09-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-26-23 | Reiterated | Citigroup | Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| May-24-23 | Reiterated | BofA Securities | Buy |
| May-24-23 | Reiterated | UBS | Buy |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Feb-15-23 | Downgrade | Societe Generale | Hold → Sell |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Sep-22-22 | Upgrade | UBS | Neutral → Buy |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Mar-10-22 | Initiated | Daiwa Securities | Outperform |
| Jan-21-22 | Upgrade | DZ Bank | Hold → Buy |
| Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-16-21 | Reiterated | BMO Capital Markets | Outperform |
| Dec-16-21 | Reiterated | BofA Securities | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Oct-11-21 | Upgrade | Berenberg | Hold → Buy |
| Sep-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Aug-05-21 | Upgrade | DZ Bank | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Jun-24-21 | Reiterated | Cantor Fitzgerald | Overweight |
| Jan-19-21 | Upgrade | Mizuho | Neutral → Buy |
| Dec-10-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Sep-03-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-16-20 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-21-20 | Downgrade | UBS | Buy → Neutral |
| Apr-09-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Dec-18-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| May-28-19 | Initiated | Goldman | Buy |
| Apr-24-19 | Upgrade | Edward Jones | Hold → Buy |
| Apr-11-19 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-12-19 | Initiated | JP Morgan | Overweight |
| Jan-23-19 | Initiated | UBS | Buy |
| Nov-26-18 | Downgrade | Citigroup | Buy → Neutral |
| Oct-31-18 | Upgrade | Credit Suisse | Underperform → Neutral |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Oct-01-18 | Reiterated | SunTrust | Buy |
| Sep-26-18 | Resumed | JP Morgan | Overweight |
View All
Lilly Eli Co Stock (LLY) Latest News
Novo Nordisk raises Eli Lilly post CagriSema data (NVO:NYSE) - Seeking Alpha
2 Dividend-Growth Stocks That Billionaire Izzy Englander Loves - The Motley Fool
Novo obesity data positive for Eli Lilly and Amgen, says UBS - Yahoo Finance
FDA says knockoff versions of Lilly obesity drug must come off the market - Wyoming Tribune
Is Now a Good Time to Buy the Dip in Eli Lilly Stock? - AOL
FDA approves Eli Lilly’s obesity medication for obstructive sleep apnea - ABC News
The FDA just approved Eli Lilly's Zepbound for sleep apnea — and Medicare coverage could be next - MSN
Eli Lilly given green light in US to treat sleep disorder with weight-loss drug - Financial Times
Lilly's weight-loss treatment Zepbound becomes first FDA-approved drug for sleep apnea - Reuters
Lilly's weight-loss drug Zepbound wins US FDA approval for sleep apnea By Reuters - Investing.com
Eli Lilly’s obesity drug Zepbound approved to treat sleep apnea in U.S. - STAT
Eli Lilly's Zepbound gains sleep apnea indication (LLY:NYSE) - Seeking Alpha
Lilly's weight-loss drug Zepbound wins US FDA approval for sleep apnea - The Denver Gazette
Lilly’s Zepbound Grabs First Drug Approval for Sleep Apnea in US - Bloomberg
FDA approves Eli Lilly's weight loss drug Zepbound for sleep apnea, expanding use in U.S. - CNBC
FDA approves Zepbound® (tirzepatide) as the first and only prescription medicine for moderate-to-severe obstructive sleep apnea in adults with obesity - Investors | Eli Lilly and Company
Eli Lilly and Company (NYSE:LLY) Trading 4.2% HigherHere's Why - MarketBeat
Nvidia, Eli Lilly lead Friday's market cap stock movers By Investing.com - Investing.com Canada
Nvidia, Eli Lilly lead Friday's market cap stock movers - Investing.com India
Lilly Cements Weight Loss Lead After Novo Trial Setback - Bloomberg
Eli Lilly: Improved Competitive Position In Obesity Market, But Strong Execution Is A Must Now - Seeking Alpha
Why Novo Nordisk Stock Got Destroyed Today, but Eli Lilly and Viking Stocks Are Up - The Motley Fool
Novo Nordisk’s next-generation weight-loss drug matches Lilly’s Zepbound in major trial, but doesn’t surpass it - CNN
Eli Lilly and Company (NYSE:LLY) Shares Gap UpHere's What Happened - MarketBeat
Eli Lilly, Avago lead market cap stock movers this Friday - Investing.com
In weight loss battle, Novo and Lilly face growing offensive from licensed copies - Reuters
LLY Stock Up as FDA Removes Mounjaro, Zepbound From Shortage List - Yahoo Finance
Stocks to Watch Friday: Trump Media, Novo Nordisk, Eli Lilly, Tesla - The Wall Street Journal
Eli Lilly shares reiterate buy rating on Phase 3 study results - Investing.com
Citi Reiterates Buy Rating on Eli Lilly (LLY) - StreetInsider.com
FedEx, Eli Lilly, Occidental rise premarket; Nike, Novo Nordisk fall - Investing.com
FDA confirms end of Eli Lilly’s tirzepatide shortage after re-evaluation - Yahoo Finance
Eli Lilly (LLY) stock: Why It’s a strong buy amid breakthrough developments - The Africa Logistics
Bernstein optimistic on Eli Lilly shares despite limited near-term impact from Tirzepatide - Investing.com
Novo Nordisk sinks on latest data, Lilly gains - Investing.com
FDA finalizes decision to end Lilly's GLP-1 shortage, analysts predict Novo will be next - Yahoo Finance
US FDA says Lilly's weight-loss drug shortage is resolved - Reuters.com
Eli Lilly & Co. stock underperforms Thursday when compared to competitors - MarketWatch
Jim Cramer on Eli Lilly and Company (LLY): ‘I See Things Going Back To Normal For Eli Lilly’ - Insider Monkey
Eli Lily GLP-1 shortage ends, FDA says: Hims & Hers stock falls - Yahoo Finance
Eli Lilly and Company (NYSE:LLY) Shares Down 1.2%Should You Sell? - MarketBeat
US FDA says Lilly’s weight-loss drug shortage is resolved - CNN
Eli Lilly dips despite FDA confirming shortage of GLP-1 tirzepatide is over - Investing.com
Eli Lilly’s (NYSE:LLY) Zepbound Shortage Over, Says FDA - TipRanks
Lilly’s US Weight-Loss Drug Shortage Ends, Curtailing Copies - Bloomberg
FDA Says Shortage of Eli Lilly’s Zepbound is Over, But Gives Compounders a Grace Period - Yahoo! Voices
Lilly’s US Weight-Loss Drug Shortage Ends, Curtailing Copycats - The Business of Fashion
Lilly’s US weight-loss drug shortage ends, curtailing copycats - Detroit News
Eli Lilly’s Zepbound Shortage Is Officially Over, FDA Says - Yahoo! Voices
Eli Lilly (LLY) Stock Price Prediction and Forecast 2025-2030 - 24/7 Wall St.
Zealand Pharma And Eli Lilly: Strategic Focus On Weight Management And Future Outlook - Seeking Alpha
Lilly Eli Co Stock (LLY) Financials Data
Revenue
Net Income
Cash Flow
EPS
17.83%
0.62%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):